Waters Corporation (NYSE:WAT) shares are up on Wednesday as the company announced FDA clearance for its Onclarity HPV Self-Collection Kit, a significant step in expanding access to cervical cancer screening.

• Waters stock is showing exceptional strength. What’s fueling WAT momentum?

Automated Processing and Clinical Validation

The U.S. Food and Drug Administration (FDA) on Wednesday cleared the Onclarity HPV Self-Collection Kit for at-home use, which is expected to enhance cervical cancer screening accessibility.

The kit, tested with the BD Onclarity HPV Assay, is the most comprehensive HPV screening tool available in the U.S., aiming to improve early detection and reduce cervical cancer deaths.

The company said the kit tested with the BD Onclarity HPV Assay can detect all of the high-risk, carcinogenic genotypes of HPV.

It is the only FDA-approved HPV assay to identify six individual and three groups of pooled results.

Samples are processed on the fully automated BD COR System, which uses advanced robotics ...